Market capitalization | $2.01b |
Enterprise Value | $2.07b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 350.66 |
P/S ratio (TTM) P/S ratio | 341.16 |
P/B ratio (TTM) P/B ratio | 4.16 |
Revenue growth (TTM) Revenue growth | -24.47% |
Revenue (TTM) Revenue | $5.89m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:
3 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:
Jun '24 |
+/-
%
|
||
Revenue | 5.89 5.89 |
24%
24%
|
|
Gross Profit | -9.79 -9.79 |
48%
48%
|
|
EBITDA | -54 -54 |
-
|
EBIT (Operating Income) EBIT | -59 -59 |
19%
19%
|
Net Profit | -88 -88 |
7%
7%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.
Head office | Australia |
CEO | Silviu Itescu |
Employees | 73 |
Founded | 2004 |
Website | www.mesoblast.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.